JP2009538284A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538284A5
JP2009538284A5 JP2009511157A JP2009511157A JP2009538284A5 JP 2009538284 A5 JP2009538284 A5 JP 2009538284A5 JP 2009511157 A JP2009511157 A JP 2009511157A JP 2009511157 A JP2009511157 A JP 2009511157A JP 2009538284 A5 JP2009538284 A5 JP 2009538284A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
pharmaceutical composition
hiv
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009511157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538284A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/068449 external-priority patent/WO2007134037A2/en
Publication of JP2009538284A publication Critical patent/JP2009538284A/ja
Publication of JP2009538284A5 publication Critical patent/JP2009538284A5/ja
Pending legal-status Critical Current

Links

JP2009511157A 2006-05-15 2007-05-08 合成抗体または抗体断片による、ヒト免疫不全ウイルス感染の治療のための方法および組成物 Pending JP2009538284A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80034206P 2006-05-15 2006-05-15
PCT/US2007/068449 WO2007134037A2 (en) 2006-05-15 2007-05-08 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments

Publications (2)

Publication Number Publication Date
JP2009538284A JP2009538284A (ja) 2009-11-05
JP2009538284A5 true JP2009538284A5 (cg-RX-API-DMAC7.html) 2010-05-20

Family

ID=38694630

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511157A Pending JP2009538284A (ja) 2006-05-15 2007-05-08 合成抗体または抗体断片による、ヒト免疫不全ウイルス感染の治療のための方法および組成物

Country Status (8)

Country Link
US (5) US8333971B2 (cg-RX-API-DMAC7.html)
EP (1) EP2016173A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009538284A (cg-RX-API-DMAC7.html)
CN (1) CN101506358B (cg-RX-API-DMAC7.html)
AU (1) AU2007249488B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0711586A2 (cg-RX-API-DMAC7.html)
CA (1) CA2651285C (cg-RX-API-DMAC7.html)
WO (1) WO2007134037A2 (cg-RX-API-DMAC7.html)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US8491896B2 (en) * 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US7906118B2 (en) * 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
US9599619B2 (en) 2002-06-14 2017-03-21 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US8821868B2 (en) 2002-06-14 2014-09-02 Immunomedics, Inc. Anti-pancreatic cancer antibodies
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
US8034352B2 (en) * 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8003111B2 (en) * 2005-04-06 2011-08-23 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US8491914B2 (en) 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US20110171126A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
US8481041B2 (en) 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
US8067006B2 (en) 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US20080171067A1 (en) * 2007-01-17 2008-07-17 Immunomedics, Inc. Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites
US8158129B2 (en) 2005-04-06 2012-04-17 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US9931413B2 (en) 2005-04-06 2018-04-03 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US20100226884A1 (en) 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
US9862770B2 (en) 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US8883162B2 (en) 2005-10-19 2014-11-11 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
WO2012024223A2 (en) * 2010-08-17 2012-02-23 Immunomedics, Inc. Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
EP2238165B1 (en) * 2008-01-07 2017-07-05 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anti-hiv domain antibodies and method of making and using same
WO2009117661A2 (en) * 2008-03-20 2009-09-24 United States Department Of The Army, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Carrier neutralization assay
US9272029B2 (en) 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
US8865876B2 (en) * 2008-06-02 2014-10-21 California Institute Of Technology Engineered lectin oligomers with antiviral activity
WO2009151646A2 (en) 2008-06-13 2009-12-17 Stc.Unm Non-invasive diagnostic agents and methods of diagnosing infectious disease
KR100953498B1 (ko) * 2009-02-13 2010-04-16 고려대학교 산학협력단 신규한 화합물, 그의 제조 방법 및 그를 포함하는 전달체
WO2010099576A1 (en) * 2009-03-04 2010-09-10 Sydney West Area Health Service Compositions and methods for enhancing immune responses
KR101704988B1 (ko) * 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
WO2010141511A2 (en) * 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
FR2949195B1 (fr) * 2009-08-24 2011-10-14 Lfb Biomedicaments Poche de stockage de solution therapeutique
CA2772572A1 (en) * 2009-08-31 2011-03-03 Ibc Pharmaceuticals, Inc. Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
IN2012DN02692A (cg-RX-API-DMAC7.html) * 2009-11-05 2015-09-04 Ct Molecular Med & Immunology
EP2509629A4 (en) * 2009-12-09 2013-06-26 Ibc Pharmaceuticals Inc DNL ("DOCK-AND-LOCK") COMPLEXES FOR INTERFERING RNA ADMINISTRATION
CN102665757A (zh) * 2009-12-09 2012-09-12 免疫医疗公司 通过双特异性抗体预靶向的用于细胞毒性药物的递送系统
EP2526421B1 (en) * 2010-01-22 2018-11-21 Immunomedics, Inc. Detection of early-stage pancreatic adenocarcinoma
US8815507B2 (en) 2010-03-18 2014-08-26 California Institute Of Technology Method and materials for the cooperative hybridization of oligonucleotides
FR2959994B1 (fr) * 2010-05-12 2012-08-24 Lfb Biotechnologies Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
DK2575908T3 (en) * 2010-06-07 2016-03-14 Univ Missouri Conjugated polymer material and uses thereof
GB201012410D0 (en) * 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
EP2635300A4 (en) * 2010-11-03 2014-04-02 Ibc Pharmaceuticals Inc DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV)
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
EP2675485A4 (en) 2011-02-15 2014-10-15 Immunomedics Inc ANTI-MUCIN ANTIBODY FOR THE EARLY RECOGNITION AND TREATMENT OF PANCREATIC CANCER
CN102212133B (zh) * 2011-03-30 2013-01-16 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用
CN112225798B (zh) 2011-05-17 2023-07-18 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
US20150320893A1 (en) * 2012-05-03 2015-11-12 Joseph M VOLPE Treatment of latent hiv infection
CN104363919A (zh) 2012-06-01 2015-02-18 Ibc药品公司 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US9452228B2 (en) 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
EP3010549A4 (en) * 2013-06-17 2017-03-15 Emory University Pathogen binding agents conjugated to radioisotopes and uses in imaging and therapeutic applications
WO2015048770A2 (en) * 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
CA2924520C (en) 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
EP3077051B1 (en) 2013-12-02 2023-04-12 The Trustees of Columbia University in the City of New York Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
CN104109670B (zh) * 2014-03-12 2018-01-05 首都医科大学附属北京安定医院 一种双链siRNA分子及其应用
EP4011910A1 (en) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
WO2016054296A2 (en) * 2014-09-30 2016-04-07 California Institute Of Technology Crosslinked anti-hiv-1 compositions for potent and broad neutralization
CN107614515B (zh) 2015-05-28 2022-03-22 免疫医疗公司 用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
MX2018002090A (es) 2015-08-24 2018-09-12 Halo Bio Rnai Therapeutics Inc Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
CA2999516A1 (en) 2015-09-30 2017-04-06 Gilead Sciences, Inc. Compounds and combinations for the treatment of hiv
PT3355913T (pt) 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
ES2819870T3 (es) 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
US11331378B2 (en) * 2016-07-26 2022-05-17 Orgenesis Inc. Prophylactic protection against viral infections
EP3601334A4 (en) * 2017-03-27 2021-03-31 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hiv
EP3797118A4 (en) 2018-05-22 2022-06-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
WO2020037009A1 (en) * 2018-08-13 2020-02-20 Flagship Pioneering Innovations V, Inc. Conjugates and methods of using the same
EP3883962A4 (en) 2018-11-21 2023-04-12 Beth Israel Deaconess Medical Center, Inc. ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)
EP4385522A1 (en) 2021-08-13 2024-06-19 Kunshan Xinyunda Biotech Co., Ltd. Microtubule inhibitor-based antibody-drug conjugate
EP4393514A1 (en) 2021-08-24 2024-07-03 Kunshan Xinyunda Biotech Co., Ltd. Antibody-drug conjugate conjugated via breakable linker
WO2023103854A1 (zh) 2021-12-09 2023-06-15 昆山新蕴达生物科技有限公司 一种亲和力改善的抗体-药物偶联物、其制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339857C (en) * 1987-05-29 1998-05-05 Cecily Rou-Yun Sun Monoclonal antibodies to gp120 which neutraleze hiv-1
WO1991010742A1 (en) * 1990-01-16 1991-07-25 Replgien Corporation Monoclonal antibody specific for non-immunodominant epitope of hiv proteins
SE9000333D0 (sv) * 1990-01-31 1990-01-31 Britta Wahren Monoklonal antikropp
US7405320B2 (en) * 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US6706252B1 (en) * 1998-10-30 2004-03-16 Rx/Ibr Corporation Method of treating disease with radioisotopes conjugated to bioactive substances
US8877901B2 (en) * 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
AU2003301841A1 (en) * 2002-05-01 2004-06-07 National Institutes Of Health Immunotherapy regimens in hiv-infected patients
JP4874090B2 (ja) * 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド 治療薬および診断薬を投与するための方法および組成物
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates

Similar Documents

Publication Publication Date Title
US9272029B2 (en) Interferon lambada-antibody complexes
AU2005313971B2 (en) Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
AU2006232310B9 (en) Improved stably tethered structures of defined compositions with multiple functions or binding specificities
JP2024150751A5 (cg-RX-API-DMAC7.html)
US20090104114A1 (en) Nanotherapeutic Colloidal Metal Compositions and Methods
JP2021516976A5 (cg-RX-API-DMAC7.html)
CN101506358B (zh) 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物
JP2024119907A (ja) 黄色ブドウ球菌(staphylococcus aureus)感染症を治療および予防するための組成物および方法
EP2354162A1 (en) Anti-CD3 antibody formulations
JP2021515566A5 (cg-RX-API-DMAC7.html)
US9498544B2 (en) Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
JP2008542278A5 (cg-RX-API-DMAC7.html)
RU2008128311A (ru) Анти-mn антитела и способы их применения
WO2007075270A2 (en) Multivalent immunoglobulin-based bioactive assemblies
NZ524199A (en) Antibodies to human IL-1beta
JP6685225B2 (ja) 形質細胞様樹状細胞の枯渇
JP2019537617A5 (cg-RX-API-DMAC7.html)
JP2002543151A5 (cg-RX-API-DMAC7.html)
JP2007524412A5 (cg-RX-API-DMAC7.html)
US20150018486A1 (en) Nanotherapeutic Colloidal Metal Compositions and Methods
JP2024161505A (ja) Hla感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用
JP2002544172A5 (cg-RX-API-DMAC7.html)
JP2022518441A5 (cg-RX-API-DMAC7.html)
TW202508630A (zh) 治療表現cd20之b細胞癌症之方法
WO2024022414A1 (zh) 一种高浓度单克隆抗体制剂及其应用